22/11/2009 (Agence Europe) - The European Medicines Agency has reviewed further information on the centrally authorised H1N1 flu pandemic vaccines Celvapan, Focetria and Pandemrix. The data on Focetria and Pandemrix indicate that a single dose of these vaccines is able to trigger an immune response that may be sufficient to give protection against the H1N1 pandemic influenza in some age groups. For both vaccines, a single dose may be used in adults aged between 18 and 60 years and in...